Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company developing ALXN1840, a late-stage therapy for Wilson disease, and a radiopharmaceutical pipeline targeting advanced cancers, including MNPR-101-Zr and MNPR-101-Lu in Phase 1 clinical trials and MNPR-101-Ac225 in late preclinical development.